HIV Pricing Programs Can Help, But More Access And Innovation Needed - IFPMA
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Innovative and generic companies both contribute to the fight against HIV/AIDS, and while putting downward pressure on prices to improve access remains important, new novel medicines are still needed, suggests a new report on access to HIV/AIDS medicines
You may also be interested in...
ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA
MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented
Sanofi Asks Thailand To Review Compulsory Licensing Policy
Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).